RecruitingPhase 2NCT06778408

Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial

Sponsor

University of Vermont Medical Center

Enrollment

103 participants

Start Date

Apr 28, 2025

Study Type

INTERVENTIONAL

Conditions

Palliative Radiotherapy Metastatic Cancer (Different Solid Tumour Types)

Summary

This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Hybrid Palliative Radiation Therapy for people with metastatic cancer (different solid tumour types) and palliative radiotherapy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.